argenx SE (NASDAQ:ARGX) Shares Bought by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lifted its position in shares of argenx SE (NASDAQ:ARGX) by 44.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,138 shares of the company’s stock after purchasing an additional 969 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in argenx were worth $1,930,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC acquired a new stake in argenx during the third quarter valued at $88,339,000. Allspring Global Investments Holdings LLC grew its position in shares of argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after acquiring an additional 143,834 shares during the period. Raymond James Financial Inc. purchased a new position in shares of argenx in the 4th quarter valued at about $43,543,000. Jennison Associates LLC raised its holdings in argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after purchasing an additional 64,183 shares during the period. Finally, Wellington Management Group LLP boosted its position in argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after purchasing an additional 55,617 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Trading Down 5.9 %

ARGX opened at $555.11 on Friday. The stock’s 50-day moving average price is $621.43 and its 200 day moving average price is $602.61. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The firm has a market cap of $33.73 billion, a price-to-earnings ratio of -630.81 and a beta of 0.60.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, research analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ARGX. HC Wainwright raised their price objective on argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday, February 28th. Guggenheim upped their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Piper Sandler boosted their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft upgraded argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.